Tazemetostat
- Generic Name
- Tazemetostat
- Brand Names
- Tazverik
- Drug Type
- Small Molecule
- Chemical Formula
- C34H44N4O4
- CAS Number
- 1403254-99-8
- Unique Ingredient Identifier
- Q40W93WPE1
- Background
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438.
Tazemetaostat was granted FDA approval on 23 January 2020.
- Indication
Tazemetostat is indicated to treat adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection. It is also indicated to treat adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an IZH2 mutation and who have received at least 2 pri...
- Associated Conditions
- Locally Advanced Epithelioid Sarcoma, Metastatic Epithelioid Sarcoma, Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma
- Associated Therapies
- -
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT04204941
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT04179864
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Genesis Healthcare Partners, San Diego, California, United States
Tazemetostat Expanded Access Program for Adults With Solid Tumors
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT03874455
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT03854474
- Locations
- 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03456726
- Locations
- 🇯🇵
1028 Eisai Trial Site, Yokohama, Kanagawa, Japan
🇯🇵1001 Eisai Trial Site, Chuo-ku, Tokyo, Japan
🇯🇵1011 Eisai Trial Site, Hiroshima, Japan
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT03348631
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Doctors Hospital, Columbus, Ohio, United States
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
- Conditions
- Stage IVA Hepatocellular Carcinoma AJCC v7Stage III Hepatocellular Carcinoma AJCC v7Stage IVB Hepatocellular Carcinoma AJCC v7Unresectable Solid NeoplasmStage IIIB Hepatocellular Carcinoma AJCC v7Stage IIIC Hepatocellular Carcinoma AJCC v7Ann Arbor Stage IV B-Cell Non-Hodgkin LymphomaStage IIIA Hepatocellular Carcinoma AJCC v7Stage IV Hepatocellular Carcinoma AJCC v7Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03217253
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
- Conditions
- Ann Arbor Stage III Hodgkin LymphomaEwing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaLow Grade GliomaRecurrent Ewing SarcomaRecurrent Langerhans Cell HistiocytosisRecurrent Malignant GliomaRecurrent RhabdomyosarcomaRefractory Malignant Glioma
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT03213665
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionOther: Laboratory Biomarker AnalysisProcedure: Bone Marrow Aspiration and BiopsyDrug: Larotrectinib SulfateProcedure: Bone ScanProcedure: Mutation Carrier ScreeningOther: Pharmacological StudyProcedure: Computed TomographyDrug: OlaparibDrug: PalbociclibDrug: Selumetinib SulfateDrug: TipifarnibDrug: ErdafitinibDrug: TazemetostatDrug: SamotolisibDrug: EnsartinibDrug: VemurafenibDrug: UlixertinibProcedure: Magnetic Resonance ImagingDrug: SelpercatinibProcedure: Positron Emission TomographyProcedure: Radionuclide ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2316
- Registration Number
- NCT03155620
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03028103
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.